Elisabeth I. Heath - Concepedia

Author

Elisabeth I. Heath

The Barbara Ann Karmanos Cancer Institute ORCID

Also Known As

Brendan Curti, Carducci, Michael A., E Heath, E I Heath, E. Heath, E. I. Heath, E.I. Heath, ELISABETH I. HEATH, Elisabeth Heath, Elisabeth I Heath

1.2K

Publications

19.7K

Citations

H-Index

121

Concepts

All Affiliations

The Barbara Ann Karmanos Cancer Institute Wayne State University Dana-Farber Cancer Institute Johns Hopkins University Memorial Sloan Kettering Cancer Center

About

Elisabeth I. Heath is an author at The Barbara Ann Karmanos Cancer Institute specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	95	8.1K
2	Health Sciences	12	12	478
3	Biochemistry	3	3	65
4	Public Health	2	2	81
5	Language Studies	1	1	13

Elisabeth I. Heath

197

Publications

17.4K

Citations

H-Index

Page 1

	Year	Citations
Integrative Clinical Genomics of Advanced Prostate Cancer Dan R. Robinson, Eliezer M. Van Allen, Yi-Mi Wu, Cell UrologyGenitourinary CancerMedicineIntegrative Clinical GenomicsCancer Genomics	2015	3.6K
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 Howard I. Scher, Michael J. Morris, Walter M. Stadler, Journal of Clinical Oncology	2016	1.5K
Genomic correlates of clinical outcome in advanced prostate cancer Wassim Abida, Joanna Cyrta, Glenn Heller, Proceedings of the National Academy of Sciences	2019	1.3K
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar, Journal of Clinical Oncology	2019	598
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer Yi-Mi Wu, Marcin Cieślik, Robert J. Lonigro, Cell Cancer ImmunosurveillanceGenitourinary CancerMedicineImmunologyTumor Immunity	2018	578
Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with Cancer Lauren M. Hamel, Louis A. Penner, Terrance L. Albrecht, Cancer Control	2016	459
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, Journal of Clinical Oncology	2020	311
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Thomas Powles, Piotr Tomczak, Se Hoon Park, The Lancet Oncology	2022	262
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial Evan Y. Yu, Daniel P. Petrylak, Peter H. O’Donnell, The Lancet Oncology UrologyPd-l1 InhibitorsGenitourinary CancerMedicineEnfortumab Vedotin	2021	250
Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM Dejuan Kong, Elisabeth I. Heath, Wei Chen, PLoS ONE	2012	214

Page 1